Home Health Novavax COVID-19 vaccine 90.4% effective in clinical trial, company says

Novavax COVID-19 vaccine 90.4% effective in clinical trial, company says

1
0


Novavax announced on Monday that its COVID-19 vaccine was found to be over 90% effective overall, and offered 100% protection against moderate and severe disease in a Phase 3 clinical trial. The company said it intends to file for FDA authorization in the third quarter. 

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Stanley C. Erck, Novavax’s president and CEO said in a statement. “These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection. Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.” 

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

This is a developing story, please continue to check back for updates.  

Previous articleEx-Celtics player suggests Kyrie Irving's ankle injury is karma after logo stomp
Next articleA humpback whale swallowed a lobster diver whole and spit him out alive: ‘It tried to eat me’

LEAVE A REPLY

Please enter your comment!
Please enter your name here